Work

RWD136 Real-World Use of Biologic Disease-Modifying Anti-Rheumatic Drugs in US Patients with Ankylosing Spondylitis: Persistence, Factors Associated with Discontinuation, and Dosing Patterns

Year: 2023

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2023.03.2165

Authors: M. Dubreuil, J.A Walsh, A. Deodhar, L.S Gensler, J.R Curtis, S. Anjohrin, O. Pilipczuk, M. Feudjo Tepie, S. Beaty, M. Mørup, V. Taieb, S. Welby

Institutions: Boston University, University of Utah, Oregon Health & Science University, University of California, San Francisco, University of Alabama at Birmingham, UCB Pharma (Belgium), UCB Pharma (United States), UCB Pharma (France)

Language: English

Topic: Spondyloarthritis Studies and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4380151365

Cites:

Cited by: 1

Related to: 10